Local Infiltration Analgesia Following Unicompartmental Knee Arthroplasty
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. Secondary end-points are morphine consumption, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 6 months after surgery.
| Condition | Intervention |
|---|---|
|
Postoperative Pain |
Drug: ropivacaine, ketorelac and epinephrine Drug: saline |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Local Infiltration Analgesia (LIA) With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Unicompartmental Knee Arthroplasty |
- The primary aim of this study was to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. [ Time Frame: April, 2007 ] [ Designated as safety issue: No ]
- Secondary end-points were morphine consumption, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores were assessed up to 6 months after surgery. [ Time Frame: September, 2007 ] [ Designated as safety issue: Yes ]
| Enrollment: | 40 |
| Study Start Date: | September 2005 |
| Study Completion Date: | September 2007 |
| Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: A
Group A (Active) receives a multimodal injection intra- and postoperatively
|
Drug: ropivacaine, ketorelac and epinephrine
In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
|
|
Placebo Comparator: P
Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
|
Drug: saline
In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
|
Detailed Description:
Postoperative pain is often severe following knee arthroplasty. Recently, a local infiltration analgesia (LIA) technique was developed by Drs Kerr and Kohan in Sydney, Australia. With this LIA-technique, a long-acting local anesthetic (ropivacaine), a nonsteroidal anti-inflammatory drug (ketorolac), and epinephrine are infiltrated intraoperatively and via an intraarticular catheter postoperatively.
The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. Secondary end-points were morphine consumption, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores were assessed up to 6 months after surgery.
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients scheduled for unicompartmental knee arthroplasty
- Aged 20-80 yrs.
- ASA physical status I-III and mobility indicating normal postoperative mobilization
Exclusion Criteria:
- Known allergy or intolerance to one of the study drugs
- Serious liver-, heart- or renal decease
- Rheumatoid arthritis
- Chronic pain or bleeding disorder
Contacts and Locations| Sweden | |
| Dept. of Orthopedic Surgery and Anesthesia and Intensive Care | |
| Orebro, Sweden, SE-70185 | |
| Principal Investigator: | Kjell Axelsson, Prof. | Orebro University Hospital, Orebro, Sweden |
More Information
No publications provided by University Hospital Orebro
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Professor Kjell Axelsson, Dept. of Anaestesiology, Örebro University, Örebro, Sweden |
| ClinicalTrials.gov Identifier: | NCT00653926 History of Changes |
| Other Study ID Numbers: | RAK-mini |
| Study First Received: | April 2, 2008 |
| Last Updated: | April 4, 2008 |
| Health Authority: | Sweden: Regional Ethical Review Board |
Keywords provided by University Hospital Orebro:
|
Postoperative pain Local infiltration analgesia Knee arthroplasty Postoperative pain management following unicompartmental knee arthroplasty |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Epinephrine Epinephryl borate Ropivacaine Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Mydriatics Adrenergic alpha-Agonists Sympathomimetics Vasoconstrictor Agents Cardiovascular Agents Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents |
ClinicalTrials.gov processed this record on May 19, 2013